Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Periodontitis - Overview
Periodontitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Periodontitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Periodontitis - Companies Involved in Therapeutics Development
Amyndas Pharmaceuticals LLC
Cellatoz Therapeutics Inc
Cells for Cells SA
Denteric Pty Ltd
Geistlich Pharma AG
GEXVal Inc
GlycoMira Therapeutics Inc
Guangzhou Saliai Stemcell Science and Technology Co Ltd
KIMS Pharmaceutical Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Noveome Biotherapeutics Inc
PerioTrap Pharmaceuticals GmbH
TGV Laboratories Inc
Periodontitis - Drug Profiles
AMY-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLZ-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXV-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIMS-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
METI-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PODOH-CRC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ranokure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Glutaminyl Cyclase for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taurolidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Periodontitis - Dormant Projects
Periodontitis - Discontinued Products
Periodontitis - Product Development Milestones
Featured News & Press Releases
Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
Dec 13, 2017: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101
Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
Mar 07, 2016: Penn Team Reverses Signs of turally Occurring Chronic Periodontitis
May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Periodontitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

 

List of Tables


Number of Products under Development for Periodontitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2020
Periodontitis - Pipeline by Cellatoz Therapeutics Inc, H1 2020
Periodontitis - Pipeline by Cells for Cells SA, H1 2020
Periodontitis - Pipeline by Denteric Pty Ltd, H1 2020
Periodontitis - Pipeline by Geistlich Pharma AG, H1 2020
Periodontitis - Pipeline by GEXVal Inc, H1 2020
Periodontitis - Pipeline by GlycoMira Therapeutics Inc, H1 2020
Periodontitis - Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H1 2020
Periodontitis - Pipeline by KIMS Pharmaceutical Co Ltd, H1 2020
Periodontitis - Pipeline by MetiMedi Pharmaceuticals Co Ltd, H1 2020
Periodontitis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Periodontitis - Pipeline by PerioTrap Pharmaceuticals GmbH, H1 2020
Periodontitis - Pipeline by TGV Laboratories Inc, H1 2020
Periodontitis - Dormant Projects, H1 2020
Periodontitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Periodontitis - Discontinued Products, H1 2020